Mosaic ImmunoEngineerng Founders
Mr. King has more than 15 years as CEO and BOD member of NASDAQ biotechnology company Peregrine Pharmaceuticals. He helped raise over $250M to advance the company's lead product and grow their CDMO business. Steve led the Peregrine team to advance the lead product from discovery through phase 3 clinical trials while growing CDMO revenues from startup to over $55M.
Mr. Lytle previously EVP, CFO of Breathe Technologies (private VC funded), successfully navigated the acquisition by Hillrom Holdings (2019). Paul has over 18 years of CFO experience with publicly traded biotechnology companies. He was instrumental in the formation of a biologics manufacturing business and raised over $250M to support business initiatives.
Jonathan K. Pokorski, Ph.D.
Dr. Pokorski is Associate Professor of NanoEngineering at the University of California San Diego. His lab is focused on combining protein and polymer science to generate new materials for drug delivery, imaging, and vaccination. Dr. Pokorski is a co-inventor of Mosaic
Steven N. Fiering, Ph.D.
Dr. Fiering is Professor of Microbiology, Immunology, and Genetics at the Geisel School of Medicine at Dartmouth College. His lab is focused on In situ vaccination to generate therapeutic anti-tumor immunity.
Dr. Fiering is a co-inventor of Mosaic ImmunoEngineering IP.
Nicole F. Steinmetz, Ph.D.
Acting Chief Scientific Officer
Dr. Steinmetz is a Professor of NanoEngineering and she is the Founding Director of the Center for Nano-ImmunoEngineering at the University of California San Diego. Research in her lab is focused on the study and development of plant virus-based nanotechnology for human and plant health applications. Dr. Steinmetz is Co-inventor of Mosaic ImmunoEngineering IP.
Robert Garnick, Ph.D.
Dr. Garnick has over 30 years of experience in drug development including 24 years at Genentech leading Quality and Regulatory. He also functioned as Regulatory
lead for 20 approved products. Dr. Garnick has a successful track record in venture capital including his experience as a founding investor in Stemcentrx (sold to AbbVie for $5.6B) and BioAnalytix.